Blood immune profile in patients with multiple sclerosis treated with ocrelizumab


  • Ocrelizumab treatment resulted in depletion of B cells and a changed T cell profile, marked by a decrease in serum neurofilament light (sNfL) levels in people with primary progressive multiple sclerosis (PPMS).

Why this matters

  • Ocrelizumab is the only disease-modifying treatment (DMT) approved in PPMS, a disease course which is typically unresponsive to DMT intervention.

  • Ocrelizumab is an anti-CD20 antibody that is understood to selectively deplete B cells; however, a subset of CD3+ T cells is also known to express CD20 and the effect of ocrelizumab on these cells and other immune cell types in people with PPMS is unknown.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.